Dr. Shermaine Shimei Wee

Position:Patent Scientist
Email:shimei.wee@spruson.com
Shermaine Wee

Academic Qualifications

Qualification Institution Year of Completion
Doctor of Philosophy in Medical SciencesKarolinska Institutet, Sweden2015
Master of Science in BiomedicineKarolinska Institutet, Sweden2010
Bachelor of Science in Life Sciences (Hons)National University of Singapore2005

Industry Experience

PositionOrganisation/InstitutionDate of Tenure
Assistant ManagerDuke-NUS Medical School10/2017 – 03/2018
Scientific AdministratorNational Cancer Centre Singapore Pte Ltd06/2015 – 10/2017
Laboratory BiologistInstitute of Molecular and Cell Biology, A*STAR09/2005 – 08/2008
Business Development ExecutiveBiofrontier Technology07/2005 – 08/2005

Selected Publications – Scientific

Publications
Niklasson M*, Maddalo G*, Sramkova Z*, Mutlu E*, Wee S*, Sekyrova P, Schmidt L, Fritz N, Dehnisch I, Kyriatzis G, Krafcikova M, Carson BB, Feenstra J, Marinescu VD, Segerman A, Haraldsson M, Gustavsson AL, Hammarström LG, Jenmalm-Jensen A, Uhrbom L, Altelaar AF, Linnarsson S, Uhlén P, Trantirek L, Vincent CT, Nelander S, Enger PØ, Andäng M. Membrane-depolarizing channel blockers induce selective glioma cell death by impairing nutrient transport and unfolded protein/amino acid responses. Cancer Res. 77(7); 1741–52, 2017.
Schmidt L, Baskaran S, Johansson P, Padhan N, Matuszewski D, Green LC, Elfineh L, Wee S, Häggblad M, Martens U, Westermark B, Forsberg-Nilsson K, Uhrbom L, Claesson-Welsh L, Andäng M, Sintorn IM, Lundgren B, Lönnstedt I, Krona C, Nelander S. Case-specific potentiation of glioblastoma drugs by pterostilbene. Oncotarget, 7(45):73200-73215, 2016.
Wee S, Niklasson M, Marinescu VD, Segerman A, Schmidt L, Hermansson A, Dirks P, Forsberg-Nilsson K, Westermark B, Uhrbom L, Linnarsson S, Nelander S, Andäng M. Selective calcium sensitivity in immature glioma cancer stem cells. PLoS One, 9(12): e115698, 2014.
Xie Y, Tan EJ, Wee S, Manser E, Lim L and Koh CG. Functional interactions between POPX2 phosphatase and mDia modulate RhoA pathways. J. Cell Sci., 121(4): 514-21, 2008.
Experience and Technical Background

Primary patent practice areas by technology:

  • Oncology
  • Genetics
  • Stem cells
  • Molecular Biology

Research/industry background:

A. General technical areas:

  • Oncology
  • Genetics/genomics
  • Stem cells
  • Molecular Biology
  • Cell Biology
  • Microbiology

B. Honours research:

  • Studied the molecular mechanisms and downstream effects involved in Aflatoxin B1 removal by Lactic Acid Bacteria.

C. Masters research:

  • Investigated the susceptibility of neuroblastoma cancer stem cells to different small molecule inhibitors.

D. PhD research:

  • Investigated the susceptibility of glioma cancer stem cells via drug screening using ion channel modulators, as well as the repurposing of known drugs as possible inhibitors of glioma cancer stem cells.
  • Discovered hit compounds that affected glioma cancer stem cells and/or differentiated glioma cells without affecting neural stem cells.
  • Discovered Analysed the genomic differences between glioma cancer stem cells and differentiated glioma cells to investigate the gene expression repertoire before and after treatment using the hit compounds from the drug screens.

E. Industry experience:

  • Team leader of Grants Management and Administration team.
  • Involved in strategic planning according to key stakeholders and senior management’s Masterplan.
  • Served as a scientific liaison with external stakeholders.
  • Extensive basic and translational research and data analysis.
  • Scientific writing and editing.

Would you like to join the Spruson & Ferguson team?


Work For Us

Contact our Expert Team

Contact Us